Abstract: Enfumafungin derivative triterpenoid antifungal compounds are used to treat and/or prevent Pneumocystis pneumonia (PCP) due to their unexpected efficacy against Pneumocystis spp. including their ability to reduce the lung burden of cyst and trophic forms of this fungi. The enfumafungin derivative triterpenoids (or pharmaceutically acceptable salts or hydrates thereof) are inhibitors of (1,3)-?-D-glucan synthesis and are useful in the treatment and/or prevention of PCP since they demonstrate potent activity against Pneumocystis spp. in in vivo models, exhibit adequate tissue penetration into lungs, and are well tolerated.

Abstract: Enfumafungin derivative triterpenoid antifungal compounds are used to decolonize fungi from anatomic areas of subjects colonized by fungi. The enfumafungin derivative triterpenoids (or pharmaceutically acceptable salts or hydrates thereof) are inhibitors of (1,3)-?-glucan synthesis and can decolonize Candida auris from body sites such as skin and mucosa. Subjects who would benefit from such decolonization include individuals colonized by Candida auris who previously suffered a Candida auris infection and favor relapse and/or may transmit the fungus to other individuals who may be susceptible.